Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Acorda Therapeutics Inc
ACORQ
Healthcare
Biotechnology
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa...
/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (OTCPK:ACORQ)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 04, 2022 4:07pm
New Press Release - Acorda Therapeutics Reports Second Quarter 2022 Financial Results
INBRIJA® (levodopa inhalation powder) Q2 2022 U.S. net revenue of $7.4 million; 16% increase from Q2 2021; 100% increase over Q1 2022 Ex-U.S. INBRIJA Q2 additional revenue of $1.9 million AMPYRA® (dalfampridine) Q2 2022 net revenue of $18.2 million; maintaining 2022 guidance of $68-$78 million ...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jul 28, 2022 4:01pm
New Press Release - Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a webcast/conference call in conjunction with its second quarter 2022 update and financial results on Thursday, August 4 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link: https://event.on24.com/wcc/r...
read article.
Join Pulsar Helium on the Ground in Minnesota for a Historic Reservoir Flow Test
posted May 03, 2024 9:00am by
Pulsar Helium Inc.
-
|
In recognition of the recent docu-film highlighting the importance of helium in healthcare we are offering investors an opportunity to join Pulsar on the ground in Minnesota for this month's historic reservoir flow tests. CLICK HERE ...read more
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jul 26, 2022 3:48pm
ACOR ....Don't give up!
I'm in it to win it ; ) Cheers !
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jul 22, 2022 12:12pm
ACOR....seriously....BTFD !
44 f'ing pesos This will be "The Next One" JMHO
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jul 20, 2022 1:47pm
ACOR.....My ST target is North of $1.30 ; )
Just my own opinion ; ) Cheers !
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jul 20, 2022 1:13pm
ACOR..... A break of $0.57 with a vol spike....
would be meaningful ; ) Cheers !
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jul 20, 2022 1:07pm
ACOR ..... Thin to win.... Lets get going !
Rally is inevitable IMHO
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jul 19, 2022 2:19pm
ACOR ...... A break of $0.52 with some vol
Place ur bets Cheers !
Prev
1
2
3
4
5
6
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon
Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company
Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results
Drill Permit Approval Received for New Mexico Lithium Project
This profitable gold stock is on its way up
An Opportunity to Join Pulsar Helium on the Ground in Minnesota for a Historic Reservoir Flow Test